Zentalis Pharmaceuticals, Inc.
ZNTL
$1.23
-$0.03-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -136.50% | 54.51% | -976.81% | 116.53% | -9.71% |
| Total Depreciation and Amortization | -1.25% | -1.83% | 0.93% | -3.86% | -3.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 853.64% | -92.12% | 184.05% | -574.22% | -17.24% |
| Change in Net Operating Assets | 2.51% | -151.48% | 186.47% | -258.79% | 114.86% |
| Cash from Operations | 9.86% | -25.35% | 32.39% | -28.02% | -5.00% |
| Capital Expenditure | -- | 100.00% | -352.50% | 76.88% | -90.11% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33.08% | 39.41% | -43.81% | 247.03% | 64.31% |
| Cash from Investing | -33.08% | 39.88% | -43.96% | 246.33% | 64.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 922.22% | -96.37% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 922.22% | 28.57% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -272.94% | 770.31% | -106.68% | 111.59% | 46.95% |